title: Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.
abstract: Glioblastoma multiforme (GBM) is an incurable brain tumor resistant to standard treatment modalities such as surgery, radiation, and chemotherapy. Since recurrent GBM tends to develop predominantly within the infiltrative rim surrounding the primary tumor focus, novel therapy strategies need in addition to focal tumor destruction to target this somewhat diffuse area. This is a phase I/II clinical study in adult patients with recurrent GBM which is aimed at evaluating biological safety, maximum tolerated dose, and antitumor efficacy of a genetically modified replication-disabled Semliki forest virus vector (SFV) carrying the human interleukin 12 (IL-12) gene and encapsulated in cationic liposomes (LSFV-IL12). The vector will be administered in doses of 1 x 10(7)-1 x 10(9) infectious particles by continuous intratumoral infusion, thus exploiting the advantages of convection-enhanced drug delivery in the brain. The present protocol is also designed to investigate systemic and local immune response and to identify factors predicting tumor response to LSFV-IL12 therapy, such as volume of extracellular space of the tumor, volume of contrast enhancing lesion, and immune status of the patients. SFV, an insect alphavirus, infects mitotic and non-mitotic cells and triggers apoptosis in tumor cells within 48-72 h. Preclinical work with the LSFV-IL12 vector in breast and prostate cancer animal models demonstrated its biosafety and some antitumor efficacy. An ongoing phase I clinical study in patients with melanoma and renal cell carcinoma seems also to confirm the biosafety of intravenously administered vectors. This protocol will be the first study of SFV-IL12 therapy of human recurrent GBM.
authors.affiliation: Department of Neurological Science, University of Liverpool, Liverpool, UK.
authors.forename: H
authors.initials: H
authors.lastname: Ren
authors.forename: T
authors.initials: T
authors.lastname: Boulikas
authors.forename: K
authors.initials: K
authors.lastname: Lundstrom
authors.forename: A
authors.initials: A
authors.lastname: Söling
authors.forename: P C
authors.initials: PC
authors.lastname: Warnke
authors.forename: N G
authors.initials: NG
authors.lastname: Rainov
mesh_terms: D000328:Adult; D002214:Capsules; D002528:Cerebellar Neoplasms / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005909:Glioblastoma / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D018664:Interleukin-12 / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D008081:Liposomes; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D012672:Semliki forest virus / Q000235:genetics / Q000502:physiology; D014779:Virus Replication
chemical_list: D002214:Capsules; D008081:Liposomes; D018664:Interleukin-12